

## Information Regarding Clinical Trial

<b>Title</b>	A Combined Phase I/II Feasibility-and-Efficacy Study of a Carbohydrate Mimotope-based Vaccine with MONTANIDE™ ISA 51 VG Combined with Neoadjuvant Chemotherapy
<b>Protocol Number</b>	“Vaccination of High Risk Breast Cancer Patients”
<b>Sponsor</b>	UAMS
<b>Investigator</b>	J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703
<b>Study Related Phone Numbers</b>	479-587-1700 (24 hours)
<b>Key Points for Study</b>	<ul style="list-style-type: none"><li>- Females, 18 years and older</li><li>- Clinical stage I, II, or III ER-positive breast cancer who will undergo standard neoadjuvant treatment</li><li>- ECOG of 0 or 1</li><li>- Must <u>not</u> have an existing diagnosis or history of autoimmune disorders or conditions of immunosuppression.</li></ul>